Our commitment to people living with chronic and serious diseases
At Novo Nordisk, we are working each and every day to develop
innovative medicines that improve the lives of people with diabetes,
obesity and other serious chronic diseases.
We believe that ensuring affordable patient access to medicines is a responsibility we share with all stakeholders across the US healthcare system. We are committed to the patients we serve and will remain engaged and support solutions to ensure that patients who need our medicines can access and afford them.
This pledge is grounded in three tenets:
- Defeating serious chronic diseases through innovative therapies and cures
- Driving comprehensive, affordable patient access
- Working to simplify the complex US healthcare system for patients
We pursue scientific innovation with focus and intention to address serious unmet patient needs through life-changing medicines.
For more than 100 years, we have been innovating in diabetes care — giving us the expertise to help defeat other serious chronic diseases, including obesity, rare diseases and cardiovascular diseases.
Novo Nordisk’s majority owner is one of the world’s largest philanthropic foundations that supports scientific and humanitarian purposes. In fact, up to 30% of our US profits go to the Novo Nordisk Foundation. This unique ownership structure provides long-term stability to our company, allowing us to take a long-term view of research while investing in and delivering life-changing medicines that not only treat, but ultimately prevent serious chronic diseases.
Today, more than 10 million people take Novo Nordisk medicines in the US. We are proud of our scientists’ work to advance treatments and improve people’s lives.
We understand that patients experience different affordability challenges and not all situations are the same — so options matter.
Unfortunately, while we do not control what patients pay for our medicines, we continue to look for solutions to the problems in the US healthcare system. Specifically, and to help as many patients as possible, Novo Nordisk continues to offer a variety of affordability options for people with or without insurance. In 2023, more than 4 million people in the US utilized one of our affordability initiatives.
As part of our long-standing commitment to comprehensive affordable patient access, Novo Nordisk has stood by our pledge for nearly a decade to limit any potential list price increases to single digits annually.
Please visit NovoCare.com for important information on our affordability offerings for diabetes, obesity and other serious chronic diseases.
The US healthcare system is complex, and too often market dynamics or policy changes can cause unintended consequences and fail to ensure savings for patients. The reality is Novo Nordisk does not control what patients pay at the pharmacy counter, and even when we offer savings or unilaterally lower our prices, those benefits don’t always reach patients.
Novo Nordisk remains steadfast in our commitment to working with policymakers and other stakeholders to advance solutions that will deliver meaningful savings for patients and their families.
